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Histopathological and Clinical Characteristics of
Secretory Carcinoma of the Breast
Abstract: Secretory breast carcinoma is a rare form of invasive breast carcinoma constituting less than 1%
of all breast cancer cases. Since insufficient data have been compiled about this rare tumor, it is important to
report every case of secretory breast carcinoma in an effort to better understand the histopathological and
clinical characteristics of this tumor and to contemplate the most appropriate therapeutic approach. In this
report, two adult female patients over 50 years of age and a 14-year-old girl were reviewed with a detailed
immunohistochemical work-up to define the clinical and molecular characteristics of secretory breast
carcinoma.
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Sekretuar Meme Kanserinin Histopatolojik ve Klinik Özellikleri
Özet: Sekretuar meme kanseri invaziv meme kanserinin nadir görülen bir tipidir ve tüm meme kanseri
olgularının % 1’inden azını oluşturur. Bu nadir tümör hakkında yetersiz bir bilgi birikimi olduğundan, en
uygun tedavi yaklaşımını planlayabilmek ve bu tümörün histopatolojik ve klinik özelliklerini daha iyi
anlayabilmek için her sekretuar meme kanseri olgusunun bildirilmesi önemlidir. Bu çalışmada, sekretuar meme
kanserinin klinik ve moleküler özelliklerini tanımlayabilmek için detaylı bir immünohistokimyasal inceleme ile
50 yaşın üzerinde iki erişkin kadın hasta ve 14 yaşında bir kız hasta gözden geçirilmiştir.
Anahtar Sözcükler: Sekretuar meme kanseri; triple negatif; immünohistokimya
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Secretory breast carcinoma (SBC) is an exceedingly rare form of invasive breast
carcinoma and constitutes less than 1% of all breast cancer cases (1). The first detailed
description of SBC was published in 1966 by McDivitt and Stewart. Seven cases in
children were reported and the young ages of the patients led to the designation of this
type of breast cancer as “juvenile carcinoma” (2). However, in the following years, SBC
was reported to occur in children and adults of all ages and both sexes (3-6). SBC in
children and young adults less than 20 years of age is associated with a very favorable
prognosis, but in elderly women the clinical course resembles that of more common
histological types of breast cancer with late recurrences and distant metastases (7).
Previously, less than 10 patients older than 50 years of age were reported (3).
Since insufficient data have been compiled about the biological behavior and clinical
course of this tumor, it would be logical to report every case of SBC in an effort to
better understand its histopathological and clinical characteristics and contemplate the
most appropriate therapeutic approach (8,9). In this report, two adult female patients
over 50 years of age and a 14-year-old girl were reviewed with a detailed
immunohistochemical work-up to define the clinical and molecular characteristics of
SBC.
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Case Reports
Case 1
A 14-year-old female patient presented with a 8x8 cm
mass that had been present for four years. Physical
examination revealed palpable lymph nodes in the left
axilla. Incisional biopsy confirmed the diagnosis. There
were no distant metastases in chest radiography,
abdominal ultrasonography (USG), and bone scintigraphy.
Modified radical mastectomy (MRM) was performed and
none of the 30 lymph nodes dissected from the axilla was
metastatic. The patient received cyclophosphamide 500
mg/m2, methotrexate 50 mg/m2, and 5-fluorouracil 500
mg/m2 on days 1 and 8, repeated every 28 days for six
cycles, due to the large tumor size. The patient is diseasefree and alive 36 months after surgery.
Case 2
A 56-year-old postmenopausal patient presented with
a 4x4 cm mass that was present for eight months in her
left breast and palpable lymph nodes in the left axilla.
Mammography revealed a high-density spiculated lesion
25 mm in diameter. Breast USG revealed a hypoechoic
and irregular solid lesion measuring 25x23x14 mm.
Histopathological tumor size was 5x5x3.5 cm after
excisional biopsy. Abdominal USG, chest radiography, and
bone scintigraphy did not reveal any distant metastases.
The patient underwent left MRM. Axillary lymph node
metastasis was present in one of the 26 dissected lymph
nodes. It was 3.5 cm in size and showed extracapsular
tumor extension. Adjuvant chemotherapy was
administered as cyclophosphamide 600 mg/m2,
doxorubicin 60 mg/m2, and 5-fluorouracil 600 mg/m2,
repeated every 21 days for six cycles. Radiotherapy was
applied to the chest wall and the axillary region due to the
large tumor size and extracapsular tumor extension in the
metastatic lymph node. The patient had no evidence of
local recurrence or distant metastases 30 months after
surgery.
Case 3
A 54-year-old postmenopausal patient presented with
a 10x10 cm mass with edematous skin in the left breast
and a 5x5 cm mass in the axilla, both of which had been
present for 18 months. She had a history of invasive
ductal carcinoma of the right breast treated with MRM
12 years before. Previously, there were no axillary
metastases and she was given six cycles of
156
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cyclophosphamide 500 mg/m2, methotrexate 50 mg/m2,
2
and 5-fluorouracil 500 mg/m on days 1 and 8, repeated
every 28 days for six cycles. Tamoxifen 10 mg bid, which
she used for six months, was recommended.
Screening results for distant spread with bone
scintigraphy, abdominal USG, and thorax computerized
tomography were normal. The patient received three
2
cycles of neoadjuvant cyclophosphamide 600 mg/m ,
2
2
doxorubicin 60 mg/m , and 5-fluorouracil 600 mg/m
chemotherapy, repeated every 21 days, and MRM was
performed. Residual tumor size was 3x3x2.5 cm and 13
out of 16 lymph nodes were metastatic in the axilla. One
more cycle of the previous chemotherapy was given
2
followed by four cycles of docetaxel 100 mg/m , repeated
every three weeks. Radiotherapy was administered to the
chest wall and the axillary region. Hormonotherapy was
given as tamoxifen 10 mg bid.
Multiple metastases were identified in bone
scintigraphy two years after the diagnosis. Zoledronic
acid 4 mg once a month and anastrozole 1 mg/day were
given. A year later, hepatic metastases were detected on
2
abdominal USG. Cisplatinum 25 mg/m and etoposide
100 mg/m2 were applied on three consecutive days,
repeated every three weeks for six cycles. The patient had
stable disease 9 months after the completion of
treatment and is alive 45 months after the diagnosis.
Histopathological Findings
Macroscopically, all of the tumors were wellcircumscribed and had a heterogeneous appearance on
their cut surface with a grayish-white to tan color. The
largest tumor diameter was 7 cm (Case 1), whereas
residual tumor sizes were 3 cm (Case 2) and 2 cm (Case
3) in diameter in the other two cases.
Microscopically, there were small, uniform glands
filled with secretory material, which was also present
extracellularly (Figure 1a, 1b). Epithelial cell nuclei were
relatively monotonous and round in shape with
inconspicuous nucleoli, and no sign of mitoses was
observed. Epithelial tumor cells lacked significant atypia
and appeared bulging due to secretory material and
vacuolated with secretory droplets. Secretory material
was periodic acid-Schiff (PAS)-positive and diastaseresistant in histochemical examination. In addition, Alcian
blue and mucicarmine stained positive both inside and
outside the tumor cells.
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Figure 1a. Secretory carcinoma of the breast (H&E X100).

Figure 1b. Secretory carcinoma of the breast (H&E X200).

Immunohistochemistry
was
performed
by
streptavidin-biotin method using antibodies for
monoclonal and polyclonal carcinoembryonic antigens
(CEA) (Neomarkers, 1/400, 1/600 dilution), actin
(Neomarkers, 1/200), S100 (Neomarkers, 1/2000
dilution), mammaglobulin (DAKO, 1/100 dilution),
estrogen (ER) and progesterone (PR) receptors, HER2
(Neomarkers, 1/250, 1/500, 1/800 dilutions), and
cytokeratin 5/6 (DAKO, 1/10 dilution).

years of age, whereas the third case was 14 years old,
reflecting the heterogeneity in patient age.

All three cases stained negative for actin and positive
for S100 and mammaglobulin. In addition, two cases
were negative for monoclonal and polyclonal CEA,
whereas the other case was strongly positive for both.
Two cases stained negative for ER, PR, and HER2 (triple
negative) (Cases 1 and 2) and the third case was ERpositive and both PR- and HER2- negative (Case 3). One
of the triple-negative cases (Case 2) stained positive for
cytokeratin 5/6, suggesting a basal-like breast carcinoma.

Discussion
Due to the rare occurrence of SBC, its clinical course is
not fully appreciated by clinicians, resulting in discrepancies
in treatment planning. SBC is not commonly diagnosed in
older patients, unlike other histological types of breast
cancer. It was first described as a disease of children, but
later detected in all ages ranging from 3 to 87, with a
median age of 25 and more than 60% of cases being older
than 20 years (5,10,11). SBC usually occurs in females,
but was also reported in young males (M/F=1/6). All cases
were female in this study and two cases were over 50

Tavassoli and Norris suggested three features of SBC
that indicate a favorable prognosis: (1) tumor size less
than 2 cm, (2) age less than 20 years at the time of
diagnosis, and (3) tumor with circumscribed margins
(10). However, all three patients presented with large
tumors and two patients were older than 50 years,
indicating a worse outcome. Adult female patients usually
present at a median age of 33. There are less than 10
patients over 50 years of age and their tumors are
thought to behave like more common histological types of
breast cancer (3).
Duration of symptoms in patients was reported to
vary from one month to 20 years (5,7). There is usually
a longer time span between the occurrence of symptoms
and treatment irrespective of age and gender. Tumors
generally present as hard, mobile lumps with welldefined margins, as in our cases. Depending on the
duration of symptoms, tumor size may vary from <1 to
16 cm (7,10). All cases in this study had large tumors and
long duration of symptoms.
Axillary and distant metastases occur less frequently
compared to other types of breast cancer, and prognosis
is better (3,5,6,12). Breast conserving surgery (BCS) can
be an option in SBC especially in prepubertal girls in
whom breast development is not yet complete. In children
and males, tumor size and location may hinder this
possibility. Some authors suggest mastectomy as the
standard treatment due to local recurrences in two-thirds
157
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of the patients treated with BCS (5,10). Richard et al.
(13) reported the local recurrence rate as 33% in 33
adult female patients treated with BCS. Mastectomy was
preferred in this study due to the large tumor size.
Axillary metastases are detected in 20-30% of SBC
patients and are rare in females with tumors <2 cm
(5,10). However, higher rates of axillary metastases are
detected in male patients with smaller tumors (3,5,10).
Complete axillary dissection has significant complications
such as pain, loss of skin sensation, seroma formation,
limitation of shoulder movements, increase in the
frequency of lymphangitis, and lymphedema (12,14).
Sentinel lymph node biopsy is an acceptable alternative to
axillary dissection especially in children with a longer life
expectancy, protecting the patients from unnecessary
morbidity (6,15). However, axillary dissection was
performed in all of our patients due to the presence of
palpable lymph nodes.
Distant metastases were previously reported in only
four patients (8,16). Case 3 presented with locally
advanced disease and distant metastases occurred in the
first two years of diagnosis. It is not possible to
determine whether these distant metastases resulted
from invasive ductal carcinoma or SBC. All previous
metastatic patients showed disease progression while on
treatment with chemotherapy (8,10,16). However,
chemotherapy resulted in stable disease for the first time
in our case with distant metastases.
SBC is a low-grade carcinoma with solid, microcystic,
and ductal architecture composed of cells that produce
large amounts of intracellular and extracellular secretions
and have vacuolated or granular eosinophilic cytoplasm
(10). Neoplastic cells are polygonal with minimal or
absent atypia and mitotic activity with accompanying
prominent nucleoli. In addition, presence of
intracytoplasmic vacuoles is a key feature for accurate
diagnosis (3). Secretions stain with Alcian blue and PAS
with and without diastase (5,7). Immunohistochemistry
generally gives positive results with cytokeratins, S100,
CEA, and alpha-lactalbumin (5,7). All of our cases showed
similar features. Epithelial cells had PAS- positive,
diastase-resistant secretory material and were
immunoreactive for mammaglobulin.
The relationship between SBC and hormone receptor
status is controversial. ER and PR status varies in all age
groups of male and female patients and pathogenesis of
SBC may be unrelated to female sex hormones (5,7).
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Based on well-differentiated nuclear features and a
diploid tumor with a low S-phase fraction in flow
cytometric studies, ER and PR positivity is anticipated
(13,17). Contrary to this expectation, most of these
tumors are hormone receptor- negative. In addition,
recent studies reported triple-negative cases after the
widespread assessment of HER2 status (8,15,18,19). All
of our cases were PR- and HER2-negative and only one
patient showed ER positivity. As a result, two patients
had triple-negative tumors. However, only one of these
cases stained positive with cytokeratin 5/6 and was
accepted as basal-like carcinoma. There is scarce
information regarding the use of hormonotherapy in
young patients; however, it can be utilized in hormone
receptor-positive patients.
There are many controversies regarding the adjuvant
treatment of SBC. While some clinicians do not
recommend adjuvant radiotherapy, some argue that this
treatment must be planned according to the risk factors
(6). In patients with small tumors and negative axilla,
radiotherapy is not necessary after mastectomy. Adjuvant
radiotherapy must follow BCS in the adult patient group
in order to decrease the local recurrence rate. However,
radiotherapy must be avoided in children, where it may
result in impairment of coastal growth and lung
complications (15). Despite the previous reports claiming
that chemotherapy has no effect on disease course,
various combination protocols are still widely used (4,8).
Due to the large tumor size and metastases in the axilla,
patients in this study received adjuvant chemotherapy.
Although there is at present no sufficient evidence to
recommend adjuvant chemotherapy and radiotherapy,
contemporary guidelines for breast cancer management
should be followed in cases with large tumor size and
axillary metastases, especially in adults.
Since SBC follows an indolent clinical course, a longterm follow-up is required to reach definite conclusions
about its clinical behavior. Treatment must be planned by
taking into consideration the histopathological
characteristics, tumor size, and axillary lymph node status
and should differ between children and adult patients.
Conservative surgery may be preferred in children and
young adults. Radiotherapy should only be used in adult
patients with risk factors such as large tumor size and
axillary lymph node metastases. Chemotherapy can be
used in both adults and children. Hormonotherapy should
be used in hormone receptor- positive adult patients.
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